Literature DB >> 17404773

Trends in laryngopharyngeal reflux: a British ENT survey.

P D Karkos1, J Benton, S C Leong, A Karkanevatos, K Badran, V R Srinivasan, R H Temple, W J Issing.   

Abstract

There is a lot of scepticism surrounding laryngopharyngeal reflux (LPR). Symptoms such as globus pharyngeus, constant throat clearing, chronic cough, idiopathic hoarseness, catarrh and choking episodes may be reflux-related. The aim of this survey was to highlight current treatment trends in LPR. Questionnaires were emailed to 260 members of the British Academy of Otolaryngology-Head and Neck surgery (BAO-HNS). Survey recipients were asked about type, duration and dose of antireflux treatment and length of follow-up appointments, if any. Finally, they were asked about awareness of any reflux symptom and reflux sign questionnaires. Survey response rate was 60%. The vast majority of the otolaryngologists surveyed believe in laryngopharyngeal reflux (90%) and more than 50% prescribe proton pump inhibitors (PPIs). The preferred duration of treatment is 2 months (37%). Only a minority will prescribe PPIs for 6 months or more. Most otolaryngologists will give the standard GORD dose (70%) (once daily) and only a few (20%) will prescribe more aggressive and prolonged doses. The commonest symptoms for which proton pump inhibitors are prescribed are globus (73%), followed by choking episodes (66%) and chronic cough (62%). If LPR is suspected, most of the otolaryngologists will follow-up the patients (61%) and approximately one third (31%) will discharge them back to the general practitioners. Only eight-percent 8% will refer to gastroenterologists. The three commonest laryngoscopic signs that makes them suspect LPR are erythema of the arytenoids (86%) or the vocal cords (57%) and granulomas (42%). The majority of the otolaryngologists (94%) do not use popular questionnaires such as the RFS or RSI. Despite the controversy surrounding laryngopharyngeal reflux, our results suggest that the majority of the otolaryngologists surveyed believe in LPR and attempt to treat it. Interesting findings are: the duration of treatment, the doses used, the length of follow-ups or the lack of, and the fact that the majority does not request any specific diagnostic tests. "symptoms and signs" questionnaires are rarely used.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404773     DOI: 10.1007/s00405-006-0222-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  6 in total

1.  Extraesophageal pediatric reflux: 24-hour double-probe pH monitoring of 222 children.

Authors:  J P Little; B L Matthews; M S Glock; J A Koufman; D M Reboussin; C J Loughlin; W F McGuirt
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1997-07

2.  Sensitive pepsin immunoassay for detection of laryngopharyngeal reflux.

Authors:  John Knight; Mark O Lively; Nikki Johnston; Peter W Dettmar; Jamie A Koufman
Journal:  Laryngoscope       Date:  2005-08       Impact factor: 3.325

Review 3.  Should otolaryngologists perform pH probe studies?

Authors:  Craig W Senders
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2006-02       Impact factor: 2.064

Review 4.  Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review.

Authors:  Petros D Karkos; Janet A Wilson
Journal:  Laryngoscope       Date:  2006-01       Impact factor: 3.325

5.  Awareness of general practitioners towards treatment of laryngopharyngeal reflux: a British survey.

Authors:  P D Karkos; L Thomas; R H Temple; W J Issing
Journal:  Otolaryngol Head Neck Surg       Date:  2005-10       Impact factor: 3.497

Review 6.  The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury.

Authors:  J A Koufman
Journal:  Laryngoscope       Date:  1991-04       Impact factor: 3.325

  6 in total
  12 in total

1.  Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.

Authors:  Yoon Se Lee; Seung-Ho Choi; Young Ik Son; Young-Hak Park; Sang Yoon Kim; Soon Yuhl Nam
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-11       Impact factor: 2.503

2.  Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.

Authors:  Mark D Wilkie; Helen M Fraser; Hemal Raja
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-30       Impact factor: 2.503

3.  Airway reflux, cough and respiratory disease.

Authors:  Ian D Molyneux; Alyn H Morice
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

4.  Ear, nose and throat (ENT) manifestations and complications of reflux.

Authors:  Sabrina Brar; Carolina Watters; Natalie Watson; Martin Birchall; Yakubu Karagama
Journal:  Frontline Gastroenterol       Date:  2022-06-07

5.  Importance of esophageal manometry and pH monitoring for the evaluation of otorhinolaryngologic (ENT) manifestations of GERD. A multicenter study.

Authors:  Fernando A M Herbella; Ciro Andolfi; Yalini Vigneswaran; Marco G Patti; Bruno R Pinna
Journal:  J Gastrointest Surg       Date:  2016-07-25       Impact factor: 3.452

Review 6.  Otolaryngological perspective on patients with throat symptoms and laryngeal irritation.

Authors:  C Gaelyn Garrett; Seth M Cohen
Journal:  Curr Gastroenterol Rep       Date:  2008-06

7.  Open-Label Observational Study for Evaluating the Short-term Benefits of Rabeprazole Medication on Laryngopharyngeal Reflux.

Authors:  Myung-Hee Shin; Soon Yuhl Nam; Young-Hak Park; Young-Ik Son
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-03-22       Impact factor: 3.372

8.  Relationship between vocal symptoms in college students and their possible causes.

Authors:  Léslie Piccolotto Ferreira; Juliana Ranzani Guerra; Camila Miranda Loiola; Ana Carolina de Assis Moura Ghirardi
Journal:  Int Arch Otorhinolaryngol       Date:  2012-07

9.  Clinical predictors for response to proton pump inhibitor treatment in patients with globus.

Authors:  Hye Kyung Jeon; Gwang Ha Kim; Mun Ki Choi; Jae Hoon Cheong; Dong Hoon Baek; Gwang Jae Lee; Hang Mi Lee; Bong Eun Lee; Geun Am Song
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

10.  Management of globus pharyngeus.

Authors:  S Kortequee; P D Karkos; H Atkinson; N Sethi; D C Sylvester; R S Harar; S Sood; W J Issing
Journal:  Int J Otolaryngol       Date:  2013-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.